Treatment
toxicity
DISEASE PROGRESSION
Patients were treated with intratumoral V937 on days 1, 3, 5, and 8 and then every 3 weeks for up to 19 sets of injections. At each injection visit, the maximum dose of V937 administered was 3 × 10Patients also received intravenous pembrolizumab (2 mg/kg solution) starting on day 8 and continuing every 3 weeks for up to 2 years or until complete response, disease progression, or intolerable toxicity, whichever occurred first. On days in which patients received both V937 and pembrolizumab, V937 was administered first.